1. Home
  2. LYEL vs HBB Comparison

LYEL vs HBB Comparison

Compare LYEL & HBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$16.70

Market Cap

401.8M

Sector

Health Care

ML Signal

HOLD

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

HOLD

Current Price

$20.44

Market Cap

252.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYEL
HBB
Founded
2018
1904
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Home Furnishings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
401.8M
252.9M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
LYEL
HBB
Price
$16.70
$20.44
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$30.60
N/A
AVG Volume (30 Days)
54.9K
15.4K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
2.38%
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$36,000.00
$606,852,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8,712.13
N/A
P/E Ratio
N/A
$76.21
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$12.72
52 Week High
$45.00
$21.84

Technical Indicators

Market Signals
Indicator
LYEL
HBB
Relative Strength Index (RSI) 33.73 54.02
Support Level $15.74 $17.95
Resistance Level $19.02 $20.44
Average True Range (ATR) 1.19 1.29
MACD -0.12 0.07
Stochastic Oscillator 19.29 66.00

Price Performance

Historical Comparison
LYEL
HBB

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.

Share on Social Networks: